Last reviewed · How we verify
imexon in combination with gemcitabine — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
imexon in combination with gemcitabine (imexon in combination with gemcitabine) — AmpliMed Corporation.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| imexon in combination with gemcitabine TARGET | imexon in combination with gemcitabine | AmpliMed Corporation | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- imexon in combination with gemcitabine CI watch — RSS
- imexon in combination with gemcitabine CI watch — Atom
- imexon in combination with gemcitabine CI watch — JSON
- imexon in combination with gemcitabine alone — RSS
Cite this brief
Drug Landscape (2026). imexon in combination with gemcitabine — Competitive Intelligence Brief. https://druglandscape.com/ci/imexon-in-combination-with-gemcitabine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab